Spotlight On... Oxford Pharmascience scouts marketing partners for new pain meds; PhRMA amps up lobbying spend; Novo Nordisk staffs up in Iran; Allergan nabs another Botox approval; and more...

Oxford Pharmascience is hunting for a marketing partner for two new pain drugs. The U.K.-based pharma started contacting big drugmakers last fall, and has now hired consultants to pursue a deal on OXPzero Ibuprofen and OXPzero Naproxen. The new meds are reformulations of the two common pain relievers, tweaked to taste better and minimize digestive upset. Release

> As the debate over drug prices escalated last year, the pharma industry trade group PhRMA hiked its lobbying spending to $18.32 million, up from $16.51 million in 2014. Report

> Denmark-based Novo Nordisk ($NVO) is staffing up in Iran and continuing work on an expanded manufacturing presence as sanctions lift in the country. Report

> Allergan ($AGN) won expanded FDA approval for Botox as a treatment for muscle spasticity; the new nod for the drug, best known as a cosmetic treatment, covers muscles in the ankle and toes. Release

> Johnson & Johnson ($JNJ) appointed AKQA to be its digital agency of record for its baby products in China. Report

And Finally... Big Pharma companies are top MBA recruiters, a recent report shows. Report

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.